Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Generics. The company supplies hospitals across its markets with generic and specialty injectable products, supported by its manufacturing facilities in the United States (US), Europe and Middle East/North Africa (MENA). The company supplies branded generic and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The company supplies oral, respiratory and other generic and specialty products to the North American retail market. Its manufacturing facilities in the US supply generic and specialty products to the US and Canada markets across a broad range of therapeutic areas, including respiratory, oncology and pain management.
Hikma Pharmaceuticals PLC có cổ tức hàng năm là 1.68 mỗi cổ phiếu, với tỷ suất là 0.00%. Cổ tức được trả nửa năm và ngày ex-dividend cuối cùng là Aug 18, 2025.